Respiratory Endotherapy Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Devices {By Diagnostic Devices (Trans Bronchial Aspiration, Biopsy forceps, Cytology Brushes, Others), By Therapeutic Devices (Bronchoscope, Bronchial Thermoplasty Systems, Pulmonary Balloon Dilation Catheter, Stents, Others)}, By End User (Peripheral Vascular Intervention, Endovascular Interventions, Cardiac, Interventional Radiology, Venous, Others), By Specialist (Hospitals, Diagnostic Centers, Ambulatory Surgical Centers), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 1.53 Billion
CAGR (2026-2031)	5.34%
Fastest Growing Segment	Diagnostic Device
Largest Market	North America
Market Size (2031)	USD 2.09 Billion

Market Overview

The Global Respiratory Endotherapy Devices Market will grow from USD 1.53 Billion in 2025 to USD 2.09 Billion by 2031 at a 5.34% CAGR. Respiratory endotherapy devices encompass a range of specialized medical instruments utilized during bronchoscopic procedures to diagnose and treat therapeutic conditions within the airway and lungs, such as airway stents, biopsy forceps, and retrieval baskets. The market is fundamentally driven by the escalating global burden of chronic respiratory disorders and an increasing clinical preference for minimally invasive interventional pulmonology techniques, which significantly reduce patient recovery times compared to traditional surgery.

However, the substantial capital investment required for advanced endoscopic equipment poses a significant challenge to widespread adoption, particularly in price-sensitive developing healthcare systems where budget constraints are prevalent. According to the American Lung Association, in 2024, approximately 235,000 individuals in the United States were estimated to be diagnosed with lung cancer, a statistic that underscores the urgent and growing necessity for accessible diagnostic and therapeutic respiratory interventions.

Key Market Drivers

The escalating global prevalence of chronic respiratory diseases and lung malignancies is fundamentally propelling the adoption of respiratory endotherapy devices. As the burden of lung conditions intensifies, healthcare providers increasingly rely on interventional pulmonology for precise tissue sampling and therapeutic intervention. This demand is directly correlated with the necessity for earlier diagnosis to improve patient outcomes. According to the International Agency for Research on Cancer (World Health Organization), February 2024, in the 'Global Cancer Burden' press release, lung cancer remained the most commonly occurring cancer worldwide with 2.5 million new cases estimated in 2022. Such high incidence rates necessitate the widespread deployment of advanced biopsy forceps and stents to manage airway obstructions and secure definitive diagnoses, ensuring that medical facilities are equipped to handle the growing patient volume.

Technological advancements in bronchoscopic imaging and robotic navigation systems further accelerate market expansion by enabling minimally invasive access to peripheral lung nodules. Modern platforms utilize real-time guidance to reach lesions previously inaccessible without surgery, thereby enhancing safety profiles. According to Intuitive Surgical, October 2024, in the 'Q3 2024 Financial Results', Ion robotic-assisted bronchoscopy procedures grew 73% compared to the third quarter of 2023, reflecting strong clinical adoption of these advanced technologies. While technology drives volume, early detection remains critical for broad market utilization. According to the American Lung Association, in 2024, the national lung cancer screening rate among those at high risk was only 16%, indicating a substantial opportunity for market growth as screening programs expand and identify more patients requiring endotherapeutic procedures.

Download Free Sample Report

Key Market Challenges

The substantial capital investment required for advanced endoscopic equipment poses a significant barrier to the growth of the Global Respiratory Endotherapy Devices Market. Healthcare facilities, particularly in price-sensitive or financially constrained systems, often struggle to allocate sufficient funds for expensive diagnostic and therapeutic instruments. This high cost of entry compels many hospitals to delay the upgrading of their inventory, thereby extending the usage of older technology and slowing the adoption rate of newer, more efficient devices. Consequently, manufacturers face extended sales cycles and reduced demand for innovative respiratory solutions, directly hampering overall market expansion.

This financial strain forces medical institutions to prioritize operational liquidity over capital improvements. When hospitals face budget deficits, the acquisition of non-urgent medical technology is frequently deferred, limiting the procurement of modern devices. According to the American Hospital Association, in 2024, the average age of capital investments for medical equipment and infrastructure increased by 7.1% in 2023. This trend of aging equipment underscores the difficulty providers face in securing the necessary capital to purchase modern respiratory endotherapy devices, thereby restricting the market's potential for growth.

Key Market Trends

The Expansion of Bronchoscopic Lung Volume Reduction Therapies is widening the therapeutic scope of the Global Respiratory Endotherapy Devices Market, moving beyond diagnostics to treat severe emphysema. This trend utilizes implantable one-way valves to occlude diseased lung segments in patients with chronic obstructive pulmonary disease who are poor surgical candidates. The rising clinical acceptance of these minimally invasive implants is directly driving revenue growth for specialized interventional pulmonology segments. According to Pulmonx Corporation, October 2024, in the 'Third Quarter 2024 Financial Results', worldwide revenue reached $20.4 million, a 15% increase compared to the prior year period, highlighting the accelerating commercial adoption of these endotherapeutic solutions.

Simultaneously, the Transition Toward Single-Use Disposable Bronchoscopes is fundamentally altering inventory management and infection control protocols. Healthcare facilities are increasingly replacing capital-intensive reusable scopes with sterile disposable alternatives to mitigate pathogen transmission risks and eliminate complex reprocessing workflows. This operational pivot significantly boosts the consumption rate of high-volume consumables, fostering sustained market expansion. According to Ambu A/S, November 2024, in the 'Annual Report 2023/24', the company's Endoscopy Solutions division recorded an organic revenue growth of 19.7% for the fiscal year, underscoring the substantial demand for single-use visualization technologies in pulmonology and related endoscopic fields.

Segmental Insights

The Diagnostic Device segment represents the fastest-growing category in the Global Respiratory Endotherapy Devices Market due to the rising necessity for early disease detection. Increasing rates of lung cancer and chronic obstructive pulmonary disease compel healthcare facilities to utilize accurate screening tools such as navigational bronchoscopy systems. This growth is supported by favorable product clearances from regulatory bodies like the US Food and Drug Administration, which encourage the utilization of minimally invasive technologies. As medical professionals prioritize timely intervention to improve patient recovery rates, the demand for reliable diagnostic equipment continues to expand significantly across the sector.

Regional Insights

North America maintains a dominant position in the global respiratory endotherapy devices market, driven primarily by the high prevalence of chronic respiratory conditions such as chronic obstructive pulmonary disease and lung cancer. The region benefits from established healthcare infrastructure and comprehensive reimbursement policies that support the widespread adoption of therapeutic endoscopic procedures. Furthermore, the presence of major industry manufacturers within the United States ensures consistent product availability. The well-defined regulatory pathways established by the U.S. Food and Drug Administration also play a critical role in facilitating timely market access for new medical devices.

Recent Developments

• In October 2024, Johnson & Johnson MedTech submitted a 510(k) filing to the U.S. Food and Drug Administration (FDA) for a new software update to its Monarch Platform. This robotic-assisted bronchoscopy system, originally designed for navigating the complex airways of the lung, is set to receive enhanced capabilities through improved integration with C-arm imaging technologies. The submission reflects the company's ongoing strategy to advance its digital and robotic ecosystem, aiming to provide physicians with greater visualization and control during minimally invasive peripheral lung procedures. This development highlights the continued investment in software innovations to optimize the performance of robotic respiratory devices.
• In August 2024, Body Vision Medical announced the release of a significant software update for its LungVision AI-driven image guidance platform. This update, labeled version 2.27, introduced an enhanced AI Tomography imaging algorithm that offers a larger field of view and improved visual fidelity for virtual bronchoscopy in peripheral airways. The new software is engineered to convert standard C-arm fluoroscopes into advanced intraoperative tomographic imaging systems, providing bronchoscopists with real-time, augmented guidance during diagnostic and therapeutic procedures. The launch underscores the company's focus on utilizing artificial intelligence to improve the precision and accessibility of lung cancer diagnosis.
• In May 2024, Fujifilm India introduced its advanced lung navigation technology, Synapse 3D, at a major interventional pulmonology event. This launch represents a significant addition to the company's respiratory solutions, offering a sophisticated three-dimensional visualization system to assist clinicians during bronchoscopic procedures. The technology is designed to facilitate precise navigation to peripheral lung lesions, which are often difficult to reach with traditional methods. By providing detailed 3D mapping and pathway planning, the system aims to enhance the diagnostic yield of bronchoscopy and support early detection of lung conditions, reinforcing the company's commitment to advancing respiratory care capabilities.
• In February 2024, Olympus Canada, a subsidiary of the global medical technology company, announced the expansion of its respiratory portfolio with the launch of the Spiration Valve System in the Canadian market. This minimally invasive device is designed for the treatment of severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The system utilizes a unidirectional valve that is placed into the patient's airways via a flexible bronchoscope to redirect airflow away from diseased parts of the lung, thereby allowing healthier tissue to function more effectively. This expansion aims to provide interventional pulmonologists in Canada with a new therapeutic option to improve breathing and quality of life for eligible patients.

Key Market Players

• Fujifilm Holdings Corporation.
• Medtronic plc.
• Johnson & Johnson.
• Smith & Nephew Plc.
• Stryker corporation.
• Olympus corporation.
• Hoya corporation.
• Steris Healthcare.
• Conmed corporation.
• Boston Scientific corporation

By Diagnostic Devices	By Therapeutic Devices	By End User	By Specialist	By Region
Trans Bronchial Aspiration Biopsy forceps Cytology Brushes Others	Bronchoscope Bronchial Thermoplasty Systems Pulmonary Balloon Dilation Catheter Stents Others	Peripheral Vascular Intervention Endovascular Interventions Cardiac Interventional Radiology Venous Others	Hospitals Diagnostic Centers Ambulatory Surgical Centers	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Respiratory Endotherapy Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Respiratory Endotherapy Devices Market , By Diagnostic Devices:

• Trans Bronchial Aspiration
• Biopsy forceps
• Cytology Brushes
• Others

• Respiratory Endotherapy Devices Market , By Therapeutic Devices:

• Bronchoscope
• Bronchial Thermoplasty Systems
• Pulmonary Balloon Dilation Catheter
• Stents
• Others

• Respiratory Endotherapy Devices Market , By End User:

• Peripheral Vascular Intervention
• Endovascular Interventions
• Cardiac
• Interventional Radiology
• Venous
• Others

• Respiratory Endotherapy Devices Market , By Specialist:

• Hospitals
• Diagnostic Centers
• Ambulatory Surgical Centers

• Respiratory Endotherapy Devices Market , By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE